Resources
commercial-bd· 30 May 2026· 8 min read
The investor-ready narrative: Series C in one deck
How clinical-stage biotechs build a story that survives the third sell-side meeting of the day.
Author
Chief Innovation Officer
$1.7bn
Median base-case peak sales for our reference oncology asset
$1.4bn
Sell-side consensus on the same asset
$340m
Gap the narrative has to close in 35 minutes
The eight-slide spine
| Slide | What weak decks put here | What strong decks put here |
|---|---|---|
| 1. Problem | Disease overview | Unmet-need ladder with one number per rung |
| 2. Asset | MoA cartoon | MoA plus the one differentiation a payer cares about |
| 3. Evidence | All trials | Pivotal plus the read-through to label |
| 4. Competition | Landscape grid | Where you win — and where you lose — with reasons |
| 5. Market | TAM/SAM/SOM | Patient-flow model with a defensible peak share |
| 6. Access | Pricing analysis underway | Country-by-country pricing corridor plus payer thesis |
| 7. Plan | Gantt | Capital-efficient path to value-inflection |
| 8. Ask | X for runway | X to milestone, with the milestone defined |
The pricing-corridor slide
This is the single slide that converts interesting science into investible asset. If you cannot defend a € band in Germany, a £ band in the UK, and a $ band in the US — with the payer thesis behind each — the asset is not Series-C ready.
How we build the pricing corridor slide (3 min walkthrough) — embed placeholder (loom:placeholder)
What the sell side will not tell you
Sell-side consensus tends to under-model two things: subsequent-therapy displacement and the AMNOG-style price-anchoring effect of the first EU launch. Both can move peak sales by 15–25%.
Walk into the next meeting with the story already written
Knowledgeable builds the investor narrative from the same evidence the payer will see — so the story holds up in slide 8 and in slide 80.
See the investor workspace